2016 Annual Meeting | Emerging Therapies in Epilepsy

Date Tuesday 04/19/16

Time 06:30 AM - 08:30 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Carl W. Bazil, MD, PhD, FAAN

Topic(s)

Learning Objectives Participants should have greater familiarity with the properties of the newest AEDs, including the latest indications and adverse effect information, and understand the role of newer AEDs in the treatment of refractory status epilepticus. Neurostimulation devices are appropriate and can be helpful in patients with refractory epilepsy; participants will have greater familiarity with appropriate referral and use of these treatments. Finally, participants will be armed with the most recent, scientific evidence on the efficacy of marijuana in epilepsy.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Medical Knowledge, Practice-based Learning and Improvement

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
06:30 AM - 07:05 AM		The Newest AEDs: Emerging Profiles and Indications Carl W. Bazil, MD, PhD, FAAN
07:05 AM - 07:40 AM		Neuromodulatory Techniques in the Treatment of Refractory Epilepsy Christianne N. Heck, MD
07:40 AM - 08:15 AM		Medical Marijuana and Cannabinoids for Epilepsy: The Hype and the Reality Daniel Friedman, MD
08:15 AM - 08:30 AM		Questions and Answers

Faculty Disclosures
Carl W. Bazil, MD, PhD, FAAN	Dr. Bazil has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medical Letter . Dr. Bazil has received publishing royalties from a publication relating to health care.
Christianne N. Heck, MD	Dr. Heck has nothing to disclose.
Daniel Friedman, MD	The institution of Dr. Friedman has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Study Consortium (non-profit). Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Meili Technology. Dr. Friedman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. Dr. Friedman has stock in Neuroview Technology. The institution of Dr. Friedman has received research support from NIH. The institution of Dr. Friedman has received research support from CDC. The institution of Dr. Friedman has received research support from Epitel. The institution of Dr. Friedman has received research support from Neuropace. Dr. Friedman has received intellectual property interests from a discovery or technology relating to health care. Dr. Friedman has received intellectual property interests from a discovery or technology relating to health care. Dr. Friedman has received publishing royalties from a publication relating to health care. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Speaker Honorarium with SK Life Sciences. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Speaker Honorarium with AAN. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Travel Reimbursement with Epilepsy Foundation of America.

��ɫ��

��ɫ��